IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

Sales for IDEXX's companion animal group unit, its biggest unit which offers diagnostics for pets and IT services to veterinary clinics, rose about 6% to $870.47 million. IDEXX forecast full-year ...

The Companion Animal Group diagnostics segment registered a 6% growth, driving the overall positive earnings performance. Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by ...

IDEXX Laboratories exceeded fourth-quarter profit and revenue estimates on sales of its animal testing products and price increases.

Truist Financial Corp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 13.9% in the 4th ...

IDEXX Laboratories, Inc.’s IDXX fourth-quarter performance was driven by the consistent strong performance of the Companion Animal Group (“CAG”) segment. Solid performance in the international markets ...

Presentation Operator Good morning, and welcome to the IDEX Laboratories 4th-Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the ...

Corporate and Companion Animal Group Finance; and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements.

The positive results were largely driven by strong growth in its Companion Animal Group (CAG) segment. Overall, Idexx enjoyed a solid quarter, reflecting its continuous progress and success in its ...